An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 2, 2014, Pages 155-175

  Powell, David A ^a  

^a Inception Sciences Canada ^*  (Canada)

Author keywords

Coenzyme A; Desaturase; Dyslipidemia; Lipid; Liver; Mono unsaturated fatty acid; Oleic; SCD; Stearic; Stearoyl

Indexed keywords

ACYL COENZYME A DESATURASE; GLUCOSE; MONOUNSATURATED FATTY ACID; OXYGENASE INHIBITOR; STEAROYL COENZYME A DESATURASE INHIBITOR; UNCLASSIFIED DRUG; XENON;

ACNE; CLINICAL STUDY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HUMAN; LIPID ANALYSIS; METABOLIC DISORDER; PATENT; REVIEW; TISSUE DISTRIBUTION; WEIGHT GAIN;

ANIMALS; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STEAROYL-COA DESATURASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892755312     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.851669     Document Type: Review

References (149)

1. Merino DM, Ma DWL, Mutch DM. Genetic variation in lipid desaturases and its impact on the development of human disease. Lipids Health Dis 2010;9:63
2. Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: Molecular mechanisms. Biochim Biophys Acta 2010;1801:252-65
3. Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 2010;21:192-7 .. An overview of potential applications and challenges for SCDbased pharmacology.
4. Kusunoki J, Kanatani A, Moller DE. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine 2006;29:91-100
5. Subramaniam S, Fahy E, Gupta S, et al. Bioinformatics and systems biology of the lipidome. Chem Rev 2011;111:6452-90
6. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005;6:169-74
7. Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol 2003;14:255-61
8. Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid Res 1995;34:139-50
9. Enoch HG, Catala A, Strittmatter P. Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme substrate interactions, and the function of lipid. J Biol Chem 1976;251:5095-103 . Early report which described the function and role of the SCD enzyme.
10. Holloway PW, Wakil SJ. Requirement for reduced diphosphopyridine nucleotide-cytochrome b5 reductase in stearyl coenzyme A desaturation. J Biol Chem 1970;245:1862-5
11. Oshino N, Imai Y, Sato R. A function of cytochrome b5 in fatty acid desaturation by rat liver microsomes. J Biochem 1971;69:155-67
12. Wang J, Yu L, Schmidt RE, et al. Characterization of hSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem Biophys Res Commun 2005;332:735-42
13. Zhang S, Yang Y, Shi Y. Characterization of human SCD2, an oligomeric desaturase with improved stability and enzyme activity by cross-linking in intact cells. Biochem J (Pt1) 2005;388:135-42
14. Lengi AJ, Corl BA. Comparison of pig, sheep and chicken SCD5 homologs: evidence for an early gene duplication event. Comp Biochem Physiol B Biochem Mol Biol 2008;150:440-6
15. Beiraghi S, Zhou M, Talmadge CB, et al. Identification and characterization of a novel gene disrupted by a pericentric inversion inv(4)(p13.1q21.1) in a family with cleft lip. Gene 2003;309:11-21
16. Sinner DI, Kim GJ, Henderson GC, Igal RA. Stearoyl CoA desaturase-5: A novel regulator of neuronal cell proliferation and differentiation. PLoS One 2012;7:e39787
17. Zhang L, Ge L, Parimoo S. Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem J 1999;340:255-64
18. Landry F, Chan CC, Huang Z, et al. Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors. J Lipid Res 2011;52:1494-9
19. Miyazaki M, Kim YC, Gray-Keller MP, et al. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 2000;275:30132-8
20. Mar-Heyming R, Miyazaki M, Weissglas-Volkov D, et al. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2008;28:1193-9
21. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriflyceridemia. J Lipid Res 2002;43:1899-907
22. Stefan N, Peter A, Cegan A, et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008;51:648-56 . Recent disclosure which provide some evidence that over expression of the SCD-enzyme may play a role in human metabolic disorders.
23. Rahman SM, Dobrzyn A, Dobrzyn P, et al. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc Natl Acad Sci USA 2003;110:11110-15
24. Scaglia N, Chisholm JW, Igal RA. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS ONE 2009;4:e6812
25. Morgan-Lappe SE, Tucker LA, Huang X, et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007;67:4390-8
26. Li J, Ding SF, Habib NA, et al. Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues. Int J Cancer 1994;57:348-52
27. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112
28. Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 2010;21:192-7
29. Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in body weight regulation. Trends Cardiovasc Med 2004;14:77-81
30. Dobrzyn P, Dobrzyn A. Stearoyl-CoA desaturase: a new therapeutic target of liver steatosis. Drug Dev Res 2006;67:643-50 . A review of therapeutic applications of SCD inhibition on liver-lipid disease.
31. Ntambi JM, Miyazaki M, Stoehr JP, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002;99:11482-6
32. Cohen P, Miyazaki M, Socci ND, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002;297:240-3
33. Binczek E, Jenke B, Holz B, et al. Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol Chem 2007;388:405-18
34. Brown JM, Chung S, Sawyer JK, et al. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008;118:1467-75
35. Xu H, Wilcox D, Nguyen P, et al. Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition. Front Biosci 2007;12:3781-94 . Study which utilized an adenovirus-mediated short hairpin interfering RNA (shRNA) was to target hepatic-specific knock down of scd1 expression in ob/ob mice.
36. Gutiérrez-Juárez R, Pocai A, Mulas C, et al. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 2006;116:1686-95
37. Jiang G, Li Z, Liu F, et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005;115:1030-8
38. Issandou M, Bouillot A, Brusq JM, et al. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models. Eur J Pharmacol 2009;618:28-36
39. Li CS, Belair L, Guay J, et al. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett 2009;19:5214-17
40. For other examples of pre-clinical efficacy observed with small-molecule SCD inhibitors, see references 53, 59, 71, 72, 74, 79, 99, 100, 101-104, 108, 126, 130 and 140
41. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 2002;43:1899-907
42. Hulver MW, Berggren JR, Carper MJ, et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metabol 2005;2:251-61
43. Liu G. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity. Curr Top Med Chem 2010;10:419-33
44. Liu G. Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opin Ther Patents 2009;19:1169-91 . Comprehensive review of the SCD patent literature from 2005-2009.
45. Dales N, Fonarev J, Fu J, et al. Spiro derivatives for the modulation of stearoyl-CoA desaturase. WO112520; 2010
46. Isabel E, Lachance N, Leclerc N, et al. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO094126; 2010
47. Glushkov A, Koltun D, Mayboroda E, et al. 3-Hydroquinazolin-4-one derivatives for use as stearoyl CoA desaturase inhibitors. WO045374; 2010
48. Gschwend HW, Kodumuru V, Liu S, Kamboj R. Pyridazine derivatives and their use as therapeutic agents. WO011653; 2005
49. Abreo M, Harvey DF, Kondratenko MA, et al. Pyridyl derivatives and their use as therapeutic agents. WO011654; 2005
50. Abreo M, Chafeev M, Chakka N, et al. Pyridazine derivatives and their use as therapeutic agents. WO011655; 2005
51. Abreo M, Harvey DF, Gschwend HW, et al. Pyridyl derivatives and their use as therapeutic agents. WO011656; 2005
52. Sviridov S, Kodumuru V, Liu S, et al. Piperazine derivatives and their use as therapeutic agents. WO011657; 2005
53. Zhang Z, Sun S, Kodumuru V, et al. Discovery of piperazin-1-yl pyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome. J Med Chem 2013;56:568-83 . Disclosure of the genesis and optimization of key SCD-inhibitor XEN103.
54. Kamboj R, Zhang Z, Fu J-M, et al. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes. WO034315;2006
55. Fu J-M, Kodumuru V, Sun S, et al. Nicotinamide derivatives and their use as therapeutic agents. WO014168; 2006
56. Kamboj R, Zhang Z, Sviridov S, et al. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors. WO034441; 2006
57. Kamboj R, Fu J-M, Kodumuru V, et al. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD). WO034312; 2006
58. Billich A, Winther MD, Goldberg YP, et al. Pyridazine derivatives and their use as therapeutic agents. WO106991; 2009
59. Meingassner JG, Aschauer H, Winiski AP, et al. Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands. J Invest Dermatol 2013;133:2091-4 . Disclosure of efficacy of SCD-inhibitor XEN103 in a preclinical efficacy model for acne application.
60. Chowdhury S, Dales N, Fonarev J, et al. Heterocyclic inhibitors of stearoyl-CoA desaturase. WO103739; 2009
61. Dales N, Zhang Z, Fu J, et al. Organic compounds. WO156484; 2009
62. Dales N, Fu J, Jia Q, et al. Pyrazole derivatives which modulate stearoyl-CoA desaturase. WO039358; 2011
63. Chaudhari SS, Thomas A, Gudade G, et al. Spirocyclic compounds as stearoyl CoA desaturase inhibitors. WO037542; 2009
64. Uto Y, Kiyotsuka Y. Pharmaceutical agent containing spiro piperidine derivatives having stearoyl-CoA desaturase-inhibitory effect. JP269850; 2009
65. Xin Z, Zhao H, Serby MD, et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett 2008;18:4298-302
66. Zhao H, Serby MD, Smith HT, et al. Discovery of 1-(4-phenoxypiperidin-1- yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett 2007;17:3388-91
67. Black C, Deschenes D, Gagnon M, et al. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO009236; 2007
68. Isabel E, Oballa R, Powell D, Robichaud J. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO143823; 2007
69. Leger S, Deschenes D, Fortin R, et al. Preparation of [1,3]thiazolo[4,5-d] pyrimidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO141455; 2008
70. Léger S, Black WC, Deschenes D, et al. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett 2010;20:499-502
71. Ramtohul YK, Black C, Chan CC, et al. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett 2010;20:1593-7
72. Isabel E, Powell DA, Black WC, et al. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett 2011;21:479-83
73. Ramtohul Y. Liver-targeted stearoyl coenzyme-A desaturase inhibitors for the treatment of diabetes [abstract 219]. Canadian Society of Chemistry Conference; June 2011; Montréal, Canada
74. Oballa RM, Belair L, Black WC, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem 2011;54:5082-96 . Disclosure of the strategy utilized by Merck to design a liver-targeted SCD-inhibitor MK-8245.
75. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
76. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
77. Fahrmayr C, Fromm MF, Konig J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 2010;42:380-401
78. Tu M, Mathiowetz AM, Pfefferkorn JA, et al. Pfizer recently published a paper on medicinal chemistry design principles for liver-targeting through OATP transporters. Curr Top Med Chem 2013;13:857-66
79. Powell DA, Black WC, Bleasby K, et al. Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy. Bioorg Med Chem Lett 2011;21:7281-6
80. Liu G. Azacycloalkane derivatives as inhibitors of delta-9-stearoyl- coenzyme A desaturase. Expert Opin Ther Pat 2009;19:885-91
81. Powell DA, Tranmer GK. An exception is the following recent patent application from Merck, which describes SCD inhibitors lacking an acidic moiety: Azetidine derivatives as inhibitors or stearoyl-coenzyme A delta-9 desaturase. WO043052; 2010
82. Ramtohul Y, Li CS, Leclerc JP. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO012573; 2009
83. Ramtohul YK, Powell DA, Leclerc JP, et al. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors. Bioorg Med Chem Lett 2011;21:5692-6
84. Leclerc JP, Li CS, Ramtohul YK. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO037225; 2010
85. Leclerc JP, Li CS, Ramtohul YK. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO025553; 2010
86. Leclerc JP, Falgueyret JP, Girardin M, et al. Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors. Bioorg Med Chem Lett 2011;21:6505-9
87. Li CS, Ramtohul YK, Leclerc JP. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO073973; 2009
88. Lachance N, Leger S, Oballa R, et al. Heterocyclic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO108268; 2010
89. Lachance N, Gareau Y, Guiral S, et al. Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. Bioorg Med Chem Lett 2012;22:980-4
90. Lachance N, Guiral S, Huang Z, et al. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acylic linker series. Bioorg Med Chem Lett 2012;22:623-7
91. Fortin R, Lachance N, Li CS, et al. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO047481; 2011
92. Leclerc JP, Li CS. Moradei, OM. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO011872; 2011
93. Tawa P, Falgueyret JP, Guiral S, et al. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1. J Biomol Screen 2011;16:506-17
94. Powell DA, Lebrun ME, Bhat S, et al. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO129625; 2009
95. Dobrzyn P, Dobrzyn A. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. Expert Opin Ther Pat 2010;20:849-53
96. Powell DA, Ramtohul Y, Lebrun ME, et al. 2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors. Bioorg Med Chem Lett 2010;20:6366-9 . Disclosure of tool inhibitor which is specific for the human SCD1 isoform over hSCD5.
97. Uto Y, Kiyotsuka Y, Kurata H, et al. Preparation of heteraryl piperidine derivatives as stearoyl CoA desaturase inhibitors. JP019013; 2009
98. Kamboj R, Zhang Z, Fu J-M, et al. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase. WO034338; 2006
99. Uto Y, Ogata T, Kiyotsuka Y, et al. Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: identification of 6-[4-(2-methylbenzoyl) piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl) amide and its plasma triglyceride-lowering effects in Zucker fatty rats. Bioorg Med Chem Lett 2010;20:341-5
100. Kurikawa N, Takagi T, Wakimoto S, et al. A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis. Biol Pharm Bull 2013;36:259-67 . Preclinical evidence that SCD-inhibitors demonstrate efficacy in models of nonalcoholic fatty liver disease.
101. Uto Y, Kiyotsuka Y, Ueno Y, et al. Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: identification of 10-{6-[5-(pyridin-3- ylmethyl)-1,3,4-oxadiazol-2-yl]-pyridazin-3-yl}-5-(trifluoromethyl)-3, 4-dihydrospiro [chromene-2,40-piperidine]. Bioorg Med Chem Lett 2010;20:746-54
102. Uto Y, Ueno Y, Kiyotsuka Y, et al. Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 10-{6-[5-(pyridin-3-ylmethyl)-1,3,4 oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,40-piperidine] analogs. Eur J Med Chem 2010;45:4788-96
103. Uto Y, Ogata T, Harada J, et al. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: discovery of 3-(2-hydroxyethoxy)-4-methoxy-N- [5-(3-trifluoromethylbenzyl) thiazol-2-yl]benzamide. Bioorg Med Chem Lett 2009;19:4151-8
104. Uto Y, Ogata T, Kiyotsuka Y, et al. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: identification of 4-ethylamino-3-(2- hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl] benzamide and its biological evaluation. Bioorg Med Chem Lett 2009;19:4159-66
105. Uto Y, Kiyotsuka Y, Kurata H, et al. Pharmaceutical agent containing novel amide derivatives having stearoyl-CoA desaturase-inhibitory effects, and use thereof. JP100548; 2010
106. Koltun DO, Parkhill EQ, Vasilevich NI, et al. Novel, potent, selective and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett 2009;19:2048-52
107. Koltun DO, Vasilevich NI, Parkhill EQ, et al. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett 2009;19:3050-3
108. Koltun DO, Zilbershtein TM, Migulin VA, et al. Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett 2009;19:4070-4 . Potent SCD inhibitor disclosed by CV Therapeutics which exhibits a liver-targeted tissue-distribution profile.
109. Zilbershtein T, Cole A, Zablocki J, et al. Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors. WO123891; 2008
110. Zablocki J, Glushkov A, Zilbershtein T, et al. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl CoA desaturase inhibitors. WO043087; 2008
111. Koltun D, Parkhill E, Boze M, et al. 3-Hydroquinazolin-4-one derivatives for use as stearoyl CoA desaturase inhibitors. WO127615; 2008
112. Koltun D, Zablocki J, Vasilevich N, et al. 2H-Benzo[B][1,4]oxazin-3-(4H)- one derivatives for use as stearoyl CoA desaturase inhibitors. US0253693; 2009
113. Koltun D, Parkhill E, Boze M, et al. 3-Hydroxyquiazolin-4-one derivatives for use as stearoyl CoA desaturase inhibitors. US0105283; 2009
114. Ivanov A, Koltun D, Vasilevich N, et al. Pyrido-and pyrimido(1,2-a) pyrimidine compounds useful as stearoyl CoA desaturase inhibitors. WO045371; 2010
115. Koltun D, Parkhill E, Boze M, et al. 3-Hydroquiazolin-4-one derivatives for use as stearoyl CoA desaturase inhibitors. WO056230; 2010
116. Koltun D, Zablocki J, Parkhill E. Pyrrolotriazinone derivatives for use as stearoyl CoA desaturase inhibitors. WO124259; 2009
117. Koltun D, Zablocki J. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors. US0253738; 2009
118. Daugan ACM. Pyrazole derivatives and use thereof as inhibitors of stearoyl-CoA desaturase. WO010560; 2009
119. Bouillot AMJ. Triazole derivatives as SCD inhibitors. WO016216; 2009
120. Bouillot AMJ, Laroze A, Trottet L. 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors. WO060053; 2009
121. Bouillot AMJ, Laroze A. Triazole derivatives as SCD inhibitors. WO060054; 2009
122. Daugan ACM, Dean AW, Fillmore MC. N-Thiazolyl-1,2,3,4-tetrahydro-6- isoquinolinecarboxamide derivatives as inhibitors of stearoyl coenzyme-A desaturase. WO150196; 2009
123. Daugan ACM. Substitute 1,6-naphthyridines for use as SCD inhibitors. WO056556; 2009
124. Khairatkarjoshi N, Shah D, Gharat LA, et al. Tissue selective stearoyl-CoA desaturase 1 inhibitors and cell based screening assay for their identification. WO035052; 2010 . This patent describes a novel cell-based screening strategy which could be used to identify SCD-inhibitors with a wider therapeutic window.
125. Gharat LA, Narayana L, Thomas A, et al. Thiazole derivatives as stearoyl-CoA desaturase inhibitors. WO007482; 2010
126. Li J, Kolosko NL. Phenoxy-pyrrolidine derivative and its use and compositions. WO019566; 2009
127. Atkinson KA, Beretta EE, Brown JA, et al. N-Benzylimidazole carboxamides as potent, orally active stearoyl CoA desaturase-1 inhibitors. Bioorg Med Chem Lett 2011;21:1621-5
128. Shipps GW, Yang Z, West R. Spirocyclic oxazepine compounds as stearoyl-coenzyme A delta-9 desaturase inhibitors. WO011506; 2011
129. Shipps GW, Yang Z, Deng Y, et al. Benzo-fused oxazepine compounds as stearoyl-coenzyme A delta-9 desaturase inhibitors. WO011508; 2011
130. Deng Y, Yang Z, Shipps Jr GW, et al. Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1). Bioorg Med Chem Lett 2013;23:791-6
131. Zoller G, Voss MD, Matter H, Herling A. 2-Heteroaryl-pyrrolo[3,4-c] pyrrole derivatives and their use thereof as SCD inhibitors. WO028761; 2010
132. Zhao H, Serby MD, Smith HT, et al. Discovery of 1-(4-phenoxypiperidin-1- yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett 2007;17:3388-91
133. Bischoff A, Raikar SN, Sammeta SR, et al. Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase. WO117659; 2009
134. Bischoff A, Subramanya H, Sundaresan K, et al. Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase. US0160323; 2010
135. Bischoff A, Sundaresan K, Koteswara Rao PB, et al. Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase. WO117676; 2009
136. Leroy I, Dupont-Passelaigue E, Valeille K, et al. Derivatives of triazines and uracils, their preparation and their application in human therapeutics. WO006962; 2010
137. Dupont-Passelaigue E, Mialhe S, Rieu JP, et al. Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors. WO015629; 2011
138. Leroy I, Dupont-Passelaigue E, Mialhe S, et al. Derivatives of nitrogen heterocycles, method for preparing same and use thereof in human therapy. WO131592; 2011
139. Swindle J, Ajioka J, Hummel HS, Robertson S. Methods of inhibiting stearoyl CoA desaturase. WO070533; 2009
140. Fajas L, Benfodda Z, Fritz V. Novel inhibitors of stearoyl-CoA- desaturase-1 and their uses. WO030312; 2011 . A very early example of in vivo anti-cancer efficacy with SCD-inhibitors.
141. Gillespie P, Goodnow RA, Erickson SD, et al. Inhibitors of stearoyl-CoA desaturase. US0149466; 2009
142. Narce M, Bellenger M, Rialland M, Bellenger S. Recent advances on stearoyl-CoA desaturase regulation in fatty liver diseases. Curr Drug Metal 2012;13:1454-63
143. Chow LS, Li S, Eberly LE, et al. Estimated plasma stearoyl co-A desaturase-1 activity and risk of incident diabetes: the atherosclerosis risk in communities (ARIC) study. Metabolism 2013;62:100-8
144. Three studies for MK-8245 are listed in the clinicaltrial.gov database: NCT00846391, NCT00790556 and NCT00972322
145. Fenner A. Kidney cancer: stearoyl-CoA desaturase: A novel therapeutic target for RCC. Nat Rev Urol 2013;10:370
146. Luyimbazi D, Akcakanat A, McAuliffe PF, et al. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 2010;9:2770-84
147. Kim SJ, Choi H, Park SS, et al. Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. Mol Cells 2011;31:371-7
148. Astarita G, Jung KM, Vasilevko V, et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One 2011;6:e24777
149. Hess D, Chisholm JW, Igel RA. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One 2010;5:e11394